AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
17 Jul 2015 11:00 AM
RNS
Holding(s) in Company
17 Jul 2015 07:05 AM
RNS
AZ completes agreement with Tillotts for Entocort
14 Jul 2015 07:00 AM
RNS
IRESSA approved by US FDA
09 Jul 2015 07:32 AM
RNS
Agreement with Tillotts on Entocort
01 Jul 2015 11:00 AM
RNS
Total Voting Rights
26 Jun 2015 12:00 PM
RNS
Change in ADS ratio
25 Jun 2015 11:30 AM
RNS
Publication of Prospectus
16 Jun 2015 02:00 PM
RNS
Director/PDMR Shareholding
03 Jun 2015 03:00 PM
RNS
Holding(s) in Company
01 Jun 2015 03:00 PM
RNS
Total Voting Rights
01 Jun 2015 03:00 PM
RNS
AstraZeneca PLC - Blocklisting Interim Review
26 May 2015 07:01 AM
RNS
UPDATE ON BRODALUMAB DEVELOPMENT PROGRAMME
13 May 2015 03:00 PM
RNS
Holding(s) in Company
08 May 2015 02:00 PM
RNS
Director/PDMR Shareholding
08 May 2015 11:00 AM
RNS
Director/PDMR Shareholding - Replacement
08 May 2015 10:00 AM
RNS
Director/PDMR Shareholding
07 May 2015 02:00 PM
RNS
Director Declaration
01 May 2015 04:00 PM
RNS
Director/PDMR Shareholding
01 May 2015 11:00 AM
RNS
Total Voting Rights
29 Apr 2015 05:30 PM
RNS
Director/PDMR Shareholding
24 Apr 2015 05:30 PM
RNS
Result of AGM
24 Apr 2015 07:02 AM
RNS
1st Quarter Results
24 Apr 2015 07:01 AM
RNS
Collaboration with Celgene on PD-L1 in haematology
24 Apr 2015 07:00 AM
RNS
AZ and Innate to collaborate in immuno-oncology
23 Apr 2015 09:00 AM
RNS
Notice of Results
17 Apr 2015 07:00 AM
RNS
Selumetinib granted Orphan Drug Designation by FDA
15 Apr 2015 07:02 AM
RNS
Tremelimumab granted Orphan Drug Designation
15 Apr 2015 07:00 AM
RNS
FDA REVIEWS SAVOR OUTCOMES STUDY RESULTS
01 Apr 2015 11:00 AM
RNS
Total Voting Rights
30 Mar 2015 03:00 PM
RNS
Director/PDMR Shareholding
19 Mar 2015 11:00 AM
RNS
Notice of AGM
19 Mar 2015 07:00 AM
RNS
COLLABORATION WITH DAIICHI SANKYO INC
18 Mar 2015 07:04 AM
RNS
POSITIVE PHASE III RESULTS FOR PT003 IN COPD
16 Mar 2015 07:00 AM
RNS
BRILINTA PEGASUS-TIMI 54 STUDY
10 Mar 2015 06:24 PM
RNS
Filing of Form 20-F with SEC
10 Mar 2015 11:00 AM
RNS
Annual Financial Report
06 Mar 2015 07:00 AM
RNS
ASTRAZENECA REFINES ITS FINANCIAL REPORTING
04 Mar 2015 11:54 AM
RNS
AZ TO PARTICIPATE IN US FDA EMDAC
03 Mar 2015 07:05 AM
RNS
Acquisition of Rights to Actavis' Portfolio
02 Mar 2015 03:00 PM
RNS
Total Voting Rights
17 Feb 2015 07:00 AM
RNS
Directorate Change
16 Feb 2015 07:00 AM
RNS
PULMICORT RESPULES® US PATENT LITIGATION DECISION
05 Feb 2015 07:02 AM
RNS
AZ to acquire Actavis' US respiratory portfolio
05 Feb 2015 07:00 AM
RNS
Final Results
04 Feb 2015 09:00 AM
RNS
Notice of Results
02 Feb 2015 02:00 PM
RNS
Total Voting Rights
22 Jan 2015 07:00 AM
RNS
MAA FOR GOUT TREATMENT LESINURAD ACCEPTED BY EMA
14 Jan 2015 07:43 AM
RNS
BRILINTA PEGASUS STUDY MEETS PRIMARY ENDPOINT
02 Jan 2015 02:00 PM
RNS
Total Voting Rights
19 Dec 2014 05:40 PM
RNS
LYNPARZA APPROVED BY THE US FDA

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.

It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It was involved in developing the Oxford–AstraZeneca COVID-19 vaccine.

Astra Zeneca share price launched at 605p in 1993.

UK 100

Latest directors dealings